Your browser is no longer supported. Please, upgrade your browser.
Settings
CLBS Caladrius Biosciences, Inc. daily Stock Chart
CLBS [NASD]
Caladrius Biosciences, Inc.
Index- P/E- EPS (ttm)-1.76 Insider Own- Shs Outstand10.63M Perf Week25.46%
Market Cap28.81M Forward P/E- EPS next Y-1.31 Insider Trans- Shs Float9.12M Perf Month16.31%
Income-18.00M PEG- EPS next Q-0.49 Inst Own18.10% Short Float- Perf Quarter14.83%
Sales- P/S- EPS this Y6.40% Inst Trans-0.77% Short Ratio- Perf Half Y-10.26%
Book/sh2.43 P/B1.12 EPS next Y31.10% ROA-46.70% Target Price10.42 Perf Year-45.69%
Cash/sh2.75 P/C0.99 EPS next 5Y- ROE-56.30% 52W Range2.00 - 5.44 Perf YTD-23.88%
Dividend- P/FCF- EPS past 5Y38.50% ROI- 52W High-50.18% Beta1.57
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low35.50% ATR0.19
Employees25 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)66.08 Volatility11.37% 6.74%
OptionableYes Debt/Eq0.00 EPS Q/Q-29.10% Profit Margin- Rel Volume2.63 Prev Close2.77
ShortableYes LT Debt/Eq0.00 EarningsNov 06 AMC Payout- Avg Volume15.24K Price2.71
Recom2.00 SMA2021.12% SMA5013.99% SMA200-8.94% Volume40,009 Change-2.17%
Nov-20-18Resumed H.C. Wainwright Buy $18.50
Aug-23-16Initiated Chardan Capital Markets Buy $6.50
Apr-29-16Upgrade H.C. Wainwright Neutral → Buy $1.25
Jan-08-16Downgrade H.C. Wainwright Buy → Neutral
Jan-07-16Downgrade Maxim Group Buy → Hold
Dec-22-15Reiterated Maxim Group Buy $12 → $4
Nov-17-19 12:06AM  Edited Transcript of CLBS earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-16-19 03:59PM  Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019 GlobeNewswire
Nov-06-19 04:05PM  Caladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-19 08:44AM  When Does Market Timing Actually Work? - November 04, 2019 Zacks
Oct-31-19 08:30AM  Caladrius Biosciences to Participate at Upcoming November Conferences GlobeNewswire
Oct-30-19 08:30AM  Caladrius Biosciences to Host 2019 Third Quarter Financial Results and Business Update Conference Call on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time GlobeNewswire
Oct-23-19 11:30AM  Is Caladrius Biosciences (NASDAQ:CLBS) In A Good Position To Deliver On Growth Plans? Simply Wall St. +5.86%
Oct-14-19 11:58AM  Edited Transcript of CLBS earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents +8.96%
08:36AM  The Market Timing Secrets No One Talks About - October 14, 2019 Zacks
Oct-01-19 08:30AM  Caladrius Biosciences to Participate at the Upcoming October Conferences GlobeNewswire
Sep-24-19 09:04AM  The Keys to Successfully Timing the Markets - September 24, 2019 Zacks
Sep-06-19 10:15AM  CORRECTING and REPLACING -- Caladrius Biosciences to Participate at the Upcoming September Conferences GlobeNewswire
Sep-05-19 04:05PM  Caladrius Biosciences to Participate at the Upcoming September Conferences GlobeNewswire
Sep-04-19 08:58AM  The Keys to Successfully Timing the Markets - September 04, 2019 Zacks
Aug-15-19 09:57AM  The Keys to Successful Timing the Markets - August 15, 2019 Zacks
Aug-08-19 04:05PM  Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update GlobeNewswire
Aug-07-19 08:30AM  Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina GlobeNewswire
Aug-05-19 10:55AM  Top Ranked Momentum Stocks to Buy for August 5th Zacks
Aug-01-19 08:30AM  Caladrius Biosciences to Host 2019 Second Quarter Financial Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. Eastern Time GlobeNewswire
Jul-25-19 03:04PM  If You Had Bought Caladrius Biosciences (NASDAQ:CLBS) Stock Five Years Ago, You'd Be Sitting On A 95% Loss, Today Simply Wall St.
11:27AM  Top Ranked Momentum Stocks to Buy for July 25th Zacks
Jul-15-19 08:30AM  Caladrius Biosciences Receives Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia GlobeNewswire +11.79%
Jun-04-19 08:30AM  Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction GlobeNewswire
May-24-19 03:53AM  Edited Transcript of CLBS earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 04:05PM  Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update GlobeNewswire
May-07-19 08:30AM  Caladrius Biosciences to Participate at the Upcoming May Conferences GlobeNewswire
May-02-19 08:30AM  Caladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time GlobeNewswire
Apr-25-19 02:23PM  How Does Caladrius Biosciences, Inc. (NASDAQ:CLBS) Affect Your Portfolio Volatility? Simply Wall St.
Apr-03-19 08:30AM  Caladrius Biosciences to Participate in Upcoming Conferences GlobeNewswire
Mar-14-19 04:23PM  Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results ACCESSWIRE
04:20PM  Caladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million ACCESSWIRE
Mar-13-19 04:05PM  Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time GlobeNewswire
Mar-11-19 02:20PM  What Kind Of Shareholder Appears On The Caladrius Biosciences, Inc.s (NASDAQ:CLBS) Shareholder Register? Simply Wall St.
08:30AM  Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day GlobeNewswire
Feb-13-19 05:26PM  Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes GlobeNewswire
Feb-05-19 08:00AM  Caladrius Biosciences to Present at Upcoming February Conferences GlobeNewswire
Jan-23-19 09:04AM  What Makes Caladrius Biosciences (CLBS) a New Buy Stock Zacks
Jan-07-19 08:00AM  Caladrius Biosciences to Participate in Upcoming January Conferences GlobeNewswire
Nov-15-18 07:25AM  Recent Analysis Shows Escalade, Caladrius Biosciences, LightInTheBox Holding Co., Vishay Intertechnology, Ceridian HCM Holding, and Avista Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-09-18 08:30AM  Caladrius Biosciences to Participate in the Inv$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare Conference GlobeNewswire -13.05%
Nov-08-18 04:05PM  Caladrius Biosciences Reports 2018 Third Quarter Financial Results GlobeNewswire +6.54%
08:30AM  Caladrius Biosciences Appoints Cynthia Schwalm to Board of Directors GlobeNewswire
Nov-02-18 08:00AM  Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET GlobeNewswire
Oct-01-18 08:36AM  Caladrius Biosciences Inc (NASDAQ:CLBS): How Does It Impact Your Portfolio? Simply Wall St.
Sep-27-18 08:00AM  Caladrius Biosciences to Participate in Upcoming October Conferences GlobeNewswire
Sep-21-18 11:24AM  Caladrius Biosciences (CLBS) Shares March Higher, Can It Continue? Zacks -8.46%
Sep-12-18 09:30AM  Is Caladrius Biosciences (CLBS) Stock Outpacing Its Medical Peers This Year? Zacks
Sep-11-18 08:00AM  Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region GlobeNewswire
Aug-09-18 04:05PM  Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results GlobeNewswire +7.77%
02:30PM  Caladrius Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:00AM  Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET GlobeNewswire
Jun-20-18 08:00AM  Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Caladrius Biosciences ACCESSWIRE +30.71%
Jun-19-18 08:00AM  Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina GlobeNewswire +67.34%
Jun-05-18 08:00AM  Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions GlobeNewswire
May-10-18 04:05PM  Caladrius Biosciences Reports 2018 First Quarter Financial Results GlobeNewswire
09:39AM  For Diabetes Patients, Management Solutions Are As Critical As Medications Market Exclusive
May-07-18 08:00AM  Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair GlobeNewswire
May-03-18 08:00AM  Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time GlobeNewswire
Apr-20-18 07:20AM  Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure ACCESSWIRE
Apr-10-18 08:00AM  Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia GlobeNewswire -5.27%
Apr-09-18 04:00PM  Caladrius Biosciences to Participate at Upcoming April Conferences GlobeNewswire
Apr-03-18 08:00AM  Caladrius Biosciences to Present at The MicroCap Conference GlobeNewswire
Mar-22-18 04:05PM  Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results GlobeNewswire
12:00PM  Caladrius Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-15-18 08:00AM  Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern Time GlobeNewswire
Mar-13-18 08:00AM  Caladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan GlobeNewswire
Mar-08-18 04:05PM  Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium GlobeNewswire -6.28%
08:00AM  Caladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes GlobeNewswire
Mar-06-18 08:00AM  Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina GlobeNewswire +8.95%
Feb-07-18 08:00AM  Caladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire
Jan-18-18 08:00AM  Caladrius Biosciences Announces Completion of Enrollment of Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes GlobeNewswire
Dec-08-17 12:33PM  ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017 Capital Cube +8.19%
Dec-01-17 08:30AM  Caladrius Biosciences to Present at the 10th Annual LD Micro Main Event GlobeNewswire
Nov-09-17 04:11PM  Caladrius Biosciences Reports 2017 Third Quarter Results GlobeNewswire +6.37%
12:50PM  Caladrius Biosciences, Inc. to Host Earnings Call ACCESSWIRE
12:05PM  What Is Caladrius Biosciences Incs (CLBS) Share Price Doing? Simply Wall St.
Nov-02-17 08:00AM  Caladrius Biosciences to Host 2017 Third Quarter Business Update Conference Call on November 9, 2017 at 4:30 p.m. Eastern Time GlobeNewswire
Nov-01-17 08:00AM  Caladrius Biosciences to Participate at Upcoming November Conferences GlobeNewswire
Oct-04-17 08:56PM  How Long Will Loss-Making Caladrius Biosciences Inc (CLBS) Survive? Simply Wall St.
Oct-02-17 08:00AM  Caladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support Clinical Study of CLBS14 in Patients with Coronary Microvascular Dysfunction GlobeNewswire
Sep-28-17 08:00AM  Caladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-12-17 06:02AM  The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals Zacks
Sep-11-17 01:39PM  Why These 4 Biotech Stocks May Not Lose Momentum Soon Zacks
Sep-08-17 01:10PM  Type 1 Diabetes May Soon Meet Its Match GuruFocus.com
Sep-07-17 08:00AM  Caladrius Biosciences to Participate at Upcoming September Conferences GlobeNewswire
Sep-05-17 08:00AM  Caladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes GlobeNewswire
Aug-10-17 04:05PM  Caladrius Biosciences Reports 2017 Second Quarter Results GlobeNewswire
12:00PM  Investor Network: Caladrius Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:00AM  Caladrius Biosciences to Host 2017 Second Quarter Results Conference Call on August 10, 2017 at 4:30 p.m. Eastern Time GlobeNewswire
Jul-19-17 08:00AM  Caladrius Biosciences Announces that 50% of Subjects Have Been Treated in the Phase 2 Clinical Trial of CLBS03 for Type 1 Diabetes GlobeNewswire
Jul-12-17 02:21PM  ETFs with exposure to Caladrius Biosciences, Inc. : July 12, 2017 Capital Cube
Jun-26-17 08:00AM  Caladrius Biosciences Joins Russell Microcap® Index GlobeNewswire
Jun-14-17 08:00AM  Invetech and Caladrius Biosciences Receive 2017 Good Design Award® for Design of a Counterflow Centrifuge Device for use in the Development of Cell Therapies PR Newswire
Jun-02-17 01:59PM  ETFs with exposure to Caladrius Biosciences, Inc. : June 2, 2017 Capital Cube
Jun-01-17 08:00AM  Caladrius Biosciences to Participate at Upcoming June Conferences GlobeNewswire
May-23-17 12:33PM  ETFs with exposure to Caladrius Biosciences, Inc. : May 23, 2017 Capital Cube
May-22-17 10:40AM  Caladrius Biosciences, Inc. :CLBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 22, 2017 Capital Cube
May-18-17 04:05PM  Caladrius Biosciences Closes the Sale of its Remaining Interest in PCT to Hitachi Chemical for $75 Million GlobeNewswire
May-15-17 05:07PM  Caladrius Biosciences Announces 2017 First Quarter Financial Results GlobeNewswire
May-09-17 08:30AM  Caladrius Biosciences to Host 2017 First Quarter Financial Results Conference Call on May 18, 2017 at 5:00 p.m. Eastern Time GlobeNewswire
Caladrius Biosciences, Inc. provides development and manufacturing services to the cell therapy industry in the United States. The company offers process development and clinical manufacturing services for therapeutic candidates in various stages of development. It is also developing CLBS03, a T regulatory cell clinical Phase II therapy targeting adolescents with type 1 diabetes. Caladrius Biosciences, Inc. has a strategic collaboration with Hitachi Chemical Co. America, Ltd. and Hitachi Chemical Co., Ltd. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.